Physician profile
Caitlin E Mccarthy
NPI 1003105842
$2,685.02
in general payments reported to CMS, 2019-2025
24 companies · $461 in 2025
The $461 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.62 · 2020: $221 · 2021: $70.61 · 2022: $593 · 2023: $884 · 2024: $364 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,636 · Education: $72.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,636.45 |
| Education | $72.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gynesonics, INC. | $546.70 | 2022-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Astellas Pharma US INC | $326.19 | 2020-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $237.25 | 2019-2025 | |
| Intuitive Surgical, INC. | $201.77 | 2023-2025 | Da Vinci Surgical System |
| Sumitomo Pharma America, INC. | $176.78 | 2023-2025 | Myfembree |
| Exeltis, USA INC. | $171.80 | 2022-2025 | Slynd |
| Channel Medsystems, INC. | $167.39 | 2023 | |
| Mayne Pharma Commercial LLC | $123.98 | 2022-2025 | |
| Hologic Sales and Service, LLC | $122.29 | 2022-2025 | Novasure, Myosure Tissue Removal Device, Aptima |
| Therapeuticsmd, INC. | $71.67 | 2020-2022 | |
| Aspira Women'S Health INC | $71.00 | 2023 | Ova1 |
| Myriad Women'S Health, INC. | $65.66 | 2023 | Myrisk |
| Merck Sharp & Dohme LLC | $63.36 | 2019-2020 | |
| Pfizer INC. | $45.58 | 2022-2023 | |
| Amag Pharmaceuticals, INC. | $44.74 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $38.31 | 2020-2023 | Paragard T 380a |
| Daiichi Sankyo INC. | $38.06 | 2019-2022 | |
| Organon LLC | $37.01 | 2022-2023 | Nexplanon |
| Smith+Nephew, INC. | $35.35 | 2023-2024 | Stravix |
| Sage Therapeutics, LLC | $23.70 | 2025 | Zurzuvae |
| Agile Therapeutics, INC. | $21.84 | 2023 | Twirla |
| Evofem Biosciences, INC. | $20.81 | 2021 | |
| Scynexis, INC. | $17.90 | 2022 | |
| Millicent US INC | $15.88 | 2025 | Femlyv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.